49. Liu Y, Mu R, Wang S, et al. Therapeutic potential of human umbilical
cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis
Res Ther. 2010; 12(6): R210.
50. Ichim TE, Harman RJ, Min WP, et al. Autologous stromal vascular
fraction cells: a tool for facilitating tolerance in rheumatic disease. Cell Immunol.
2010; 264(1): 7-17. doi: 10.1016/j.cellimm.2010.04.002.
51. Rodriguez JP, Murphy MP, Hong S, et al. Autologous stromal vascular
fraction therapy for rheumatoid arthritis: rationale and clinical safety. Int Arch
Med. 2012 Feb 8; 5: 5. doi: 10.1186/1755-7682-5-5.
52. Wang L, Wang L, Cong X, et al. Human umbilical cord mesenchymal
stem cell therapy for patients with active rheumatoid arthritis: Safety and
efficacy. Stem Cells Dev. 2013 Dec 15; 22(24): 3192-202. doi:
10.1089/scd.2013.0023.
53. Mesoblast, Ltd. A double-blind, randomized, placebo-controlled, dose-
escalation, multi-center study a single intravenous infusion of allogeneic
mesenchymal precursor cells (MPCs) in patients with rheumatoid arthritis and
incomplete response to at least one TNF-alpha inhibitor. In: ClinicalTrials.gov
[Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2016
Jul 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT01851070 NLM
Identifier: NCT01851070.
54. Alliancells Bioscience Corporation Limited. Safety and efficacy study of
umbilical cord-derived mesenchymal stem cells for rheumatoid arthritis (RA). In:
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US).
2000-
[cited
2016
Jul
7].
Available
from:
https://clinicaltrials.gov/ct2/show/NCT01547091
NLM
Identifier:
NCT01547091.
55. Shenzhen Hornetcorn Bio-technology Company, LTD. Human umbilical
cord-mesenchymal stem cells for rheumatoid arthritis. In: ClinicalTrials.gov
[Internet]. Available from: https://clinicaltrials. gov/ct2/show/NCT02643823.
NLM Identifier: NCT02643823.
